Analysis of Antibacterial Drug Use and Resistance in Psychiatric Hospitals During the COVID-19 Epidemic

Study Background and Research Question

The COVID-19 pandemic has exposed vulnerabilities in healthcare systems worldwide, particularly regarding infection control and antimicrobial stewardship. Psychiatric hospitals represent a unique subset of medical institutions where physical health, infection risk, and mental health management intersect. Patients in these settings often experience impaired immunity and reduced self-care, which can increase susceptibility to bacterial infections. Moreover, the closed and communal nature of psychiatric facilities exacerbates the risk of outbreaks. Against this backdrop, the reference study sought to systematically evaluate patterns of antibacterial drug use and bacterial resistance in a psychiatric hospital during the 2022 epidemic, aiming to inform rational antibiotic use and infection control strategies.

Key Innovation from the Reference Study

This work distinguishes itself by focusing on a psychiatric hospital population—a group underrepresented in antimicrobial surveillance literature—during a period of heightened infection risk. The study’s innovation lies in its integration of hospital information systems with a national antibacterial drug monitoring network, allowing for high-resolution tracking of antibiotic usage metrics, resistance patterns, and cost analysis relative to regional and national benchmarks. This approach provides actionable insights for tailoring stewardship interventions in psychiatric care, where both overuse and underuse of antibiotics can have significant consequences.

Methods and Experimental Design Insights

The investigators conducted a retrospective analysis using data from the hospital's information system and the National Antibacterial Drug Clinical Application Monitoring Network. Key quantitative parameters included:

• Antibiotic use rate (proportion of patients receiving antibiotics)
• Antibiotic use intensity (AUD)
• Combined medication rate (proportion receiving multiple antibiotics)
• Cumulative defined daily doses (DDDs)
• Percentage of antibiotic costs in total drug expenses
• Microbiological submission rates (proportion of antibiotic use cases with microbiological testing)
• Species and resistance patterns of bacterial pathogens identified

Antibiotic utilization was classified by agent type, with third-generation cephalosporins, penicillins, and quinolones being the most frequently used. Resistance data were extracted from laboratory-confirmed microbiological results and drug sensitivity testing.

Protocol Parameters

• Data timeframe: January 1 to December 31, 2022.
• Key antibiotics monitored: Cefodizime, amoxicillin, piperacillin–tazobactam.
• Resistance testing: Conducted on all positive isolates from clinical samples; results aggregated for Gram-negative and Gram-positive bacteria separately.
• Microbiological submission: Required for 77.78% of antibiotic use cases, exceeding regional and national averages.
• Cost monitoring: Antibiotic expenditures calculated as a percentage of total drug costs for benchmarking.

Core Findings and Why They Matter

The psychiatric hospital demonstrated a notably low antibiotic use rate (5.00%), low usage intensity (AUD 3.07), and a cumulative DDDs of 12,039.04 compared to provincial and national reference levels. Antibiotic costs accounted for just 3.95% of total drug expenses, suggesting effective cost containment. However, the study found a high microbiological submission rate (77.78%), emphasizing a commitment to evidence-based prescribing and resistance monitoring.

In terms of resistance, Gram-negative bacteria exhibited pronounced resistance to penicillins, cephalosporins, and quinolones, particularly ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin. Gram-positive isolates were most resistant to penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin. These findings are consistent with broader trends of rising resistance among both Gram-negative and Gram-positive pathogens in settings where antibiotic exposure is frequent.

The study’s nuanced conclusion is that, while overall antimicrobial use in this psychiatric hospital was appropriate and below average, the inevitable rise in resistance with increased antibiotic use underscores the ongoing need for robust surveillance and stewardship. The data support targeted interventions to optimize therapy and reduce the risk of multidrug-resistant organisms, which is crucial for safeguarding treatment efficacy and patient prognosis (see full study).

Comparison with Existing Internal Articles

While the reference study is focused on antibiotic stewardship and resistance in psychiatric hospitals, prior internal resources have primarily addressed anti-inflammatory research and cell-based assay optimization, particularly with agents such as gamma-linolenic acid (GLA). For instance, internal guidance on GLA discusses its role as a weak leukotriene B4 receptor antagonist and its utility in apoptosis assay workflows—a mechanistic domain distinct from antibiotic resistance, but one that also hinges on careful protocol design and evidence-based compound selection.

Articles such as GLA: Mechanistic Benchmarks and GLA in Cell-Based Assays reinforce the importance of reproducible workflows, validated compound profiles, and robust data interpretation—principles that are equally vital in antimicrobial stewardship, even though the molecular targets and clinical objectives differ. The emphasis on protocol precision and outcome monitoring in these resources parallels the study’s approach to resistance surveillance and antibiotic use optimization.

Limitations and Transferability

The retrospective, single-institution design of the study limits direct generalizability to other psychiatric or general hospitals, especially those with substantially different patient demographics, infection control practices, or regional resistance profiles. Surveillance was conducted over a single year (2022), corresponding to an exceptional pandemic period, which may not reflect typical trends in non-epidemic years. Additionally, the study did not directly assess clinical outcomes relative to specific resistance patterns, nor did it explore molecular mechanisms of resistance development. Despite these constraints, the methodological framework—integrating national benchmarking, cost analysis, and high microbiological submission rates—offers a transferable template for other psychiatric care environments seeking to enhance their antibiotic stewardship programs.

Research Support Resources

For researchers aiming to investigate mechanisms of inflammation, cell death, or compound screening in infection-related contexts, Gamma-linolenic acid (GLA) (SKU C5518) is available as a rigorously characterized omega-6 polyunsaturated fatty acid. GLA’s established anti-inflammatory and cytotoxic properties—alongside its use in apoptosis assays and disease models such as atopic dermatitis and distal diabetic polyneuropathy—make it a relevant tool for supporting workflows that intersect with anti-inflammatory research and cellular response studies. APExBIO provides detailed product specifications, including purity, solubility, and recommended storage, to facilitate reproducible experimental design.